Novocure Limited · NASDAQ:NVCR
Novocure — Investor Presentation (July 2024)
30 slides from Novocure's investor presentation, July 2024
Slide 1: Novocure July 2024
novecure’ Novocure July 2024 patientforward”
Slide 2: Forward-looking statements
novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding a
Slide 3: 2023 achievements and 2024 milestones ahead
2025 achievements and 2024 milestones ahead DRIVING COMMERCIAL ADVANCING ADOPTION CLINICAL TRIALS 2023 France reimbursement LUNAR data presented New array launched ACHIEVEMENTS — achieved and launch LUNAR USS. FDA PMA, CE Mark in Europe and Japanese PMDA submitted New array FDA PMA METIS enrollment
Slide 4: Together with our patients, we strive to extend survival
together with our patients, we Strive to extend survival in some of the most aggressive forms of cancer patientforward’ o224Novoctre GnbH. 4
Slide 5: Tumor Treating Fields are selectively tuned electric fields
novocure’ Tumor Treating Fields (TTFields) are selectively tuned electric fields that exert physical forces to kill cancer cells TUNED ELECTRIC FIELDS DISRUPT PROTEINS DURING CELL DIVISION CAUSING CANCER CELL DEATH TTFields 100 to 500 kHz tumor cell healthy cell patientforward® © 2024 Novocure GmbH
Slide 6: Optune Gio wearable cancer therapy system
novecure’ Optune Gio® wearable cancer therapy system DELIVERS CONTINUOUS TUMOR TREATING FIELDS THERAPY TO SOLID TUMORS TWO PRIMARY COMPONENTS electric field generator and transducer arrays TTT ae patientforward” Optune Gio® is intended as a treatment for adult patients (22 years of age or older) wit
Slide 7: Strategy for long-term growth
novecure’ Strategy for long-term growth drive commercial advance deliver adoption clinical trials product innovation in approved to reach new patient to increase dose and indications populations duration of therapy patientforwa rd © 2024Novocure GmbH 7
Slide 8: Deliver pipeline
DELIVER PIPELINE GBM, glioblastoma
Slide 9: Optune Gio: established in glioblastoma
novecure’ Optune Gio: established in glioblastoma SSOOM+ 3,963 ANNUAL NET REVENUE (2023) ACTIVE PATIENTS ON THERAPY* NCCN Category 1 30-40% GUIDELINE RECOMMENDATION PENETRATION IN KEY COUNTRIES reimbursement robust intellectual ACROSS MAJOR GLOBAL MARKETS property PORTFOLIO WITH MATERIAL PRODUCT DEV
Slide 10: Optune Gio is proven to extend patient survival
novecure’ Optune Gio Is proven to extend patient survival EF-14 PHASE 3 PIVOTAL STUDY IN NEWLY DIAGNOSED GBM Overall survival (5-year survival analysis) na wm oonne 0 TA oA means | 229 | 180 NEARLY HALF Log-rank P-value <0,001 ° of ( + 84 HR (95% Cl) 0.63 (0.53-0.78) 43% Paes Veni] 3 - Snot Median O
Slide 11: Optune Gio: greater exposure increased survival
novecure’ Optune Gio: greater exposure increased survival MEDIAN OVERALL SURVIVAL BY PERCENT OF TIME ON OPTUNE GIO 25 months P-0.05 22 months P<0.05 20 months P<0.05 Optune Gio # TMZ OF PATIENTS RECEIVED A SURVIVAL 18 months 0.05 BENEFIT FROM OPTUNE GIO BECAUSE mTMZ alone 16 months THEY USED IT >50%
Slide 12: Real-world evidence demonstrates long and durable survival benefit
novecure’ real-world evidence demonstrates long and durable survival benefit with Optune Gio, consistent with EF-14 _ a eee OVERALL SURVIVAL FOR U.S. PATIENTS - FROM OPTUNE GIO START (N=974) 4 1 % ie) POST-PROGRESSION SURVIVAL FOR PATIENTS CONTINUING OPTUNE GIO (N=59)4 24% so mee = 0 (OXxicity INCRE
Slide 13: Phase 3 LUNAR trial in NSCLC met primary endpoint
novecure’ phase 3 LUNAR trial in NSCLC met primary endpoint STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS 10 Median OS (months) 32 99 oo 4 Log-rank P-value 0.035, HR (95% Ci) 0.74 (0.56-0.98) 08 + 3-year survival (95% Cl) 18% (11-27) | 7% (2-15) TTFields g 074 *S0C I TiFields
Slide 14: Significant opportunity to treat NSCLC patients
Significant opportunity to treat NSCLC patients 114K stage IV NSCLC 1L patients in the U.S. ~530,000 >7 YEA RS since any therapy 60% has shown a significant improvement in overall survival in 50% 2L NSCLC progress and seek 2L treatment receive 1L platinum-based chemotherapy forward © 2024 Novocure G
Slide 15: Preparing for 2024 NSCLC launch
novecure’ preparing for 2024 NSCLC launch 5 2023 O 2024 2025 L COMMERCIAL LAUNCH REGULATORY PATHWAY v HCP and patient campaigns ¥ Technical file submitted in EU ¥ DTC campaign echnical file submitted in CLINICAL DATA ; ¥ Global advisory boards v¥ PMA accepted for review at FDA v Announced top-line r
Slide 16: Pipeline of ongoing trials
PHASE 3 METIS TTFields monotherapy treating brain metastases NON-SMALL CELL NselKe LUNG CANCER LUNAR-2 TTFields + pembrolizumab + chemothera| treating 1L metastatic NSCLC PHASE 2 KEYNOTE-B36 TTFields therapy + pembrolizumab treating 1L advanced or metastatic NSCLC LUNAR-4 TTFields + ICI treating 2L
Slide 17: Significant pipeline catalysts on foundation of positive cashflow business
novecure’ Significant pipeline catalysts on foundation of positive cashflow business METIS DATA LUNG APPROVALS & LAUNCH 2024 CATALYSTS PANOVA-3 DATA PROFITABLE GBM BUSINESS patientforward* = © 2024 Novocure GmbH 17
Slide 18: Appendix
novecure’ appendix patientforward”
Slide 19: Therapy is frequency-tuned to target dividing cancer cells
novecure’ therapy is frequency-tuned to target dividing cancer cells | ——— TUMOR TREATING FIELDS 150 kHz 200 kHz Normal ntestine Intestin | | 50kHz 100 kHz 150 kHz 200 kHz 10 kHz 250 kHz Low Frequencies Intermediate High Frequencies DNA Damage cardiac defibrillator Frequencies radiofrequency ablatio
Slide 20: TTFields have multiple, distinct mechanisms of action
novecure’ TT Fields have multiple, distinct mechanisms of action disruption of 4 = , mitosis “ E mechanisms work together to selectively target and disrupt the progression of cancer cells, which can lead downregulation of . to their death DNA damage response patientforward” RominiyiO, et al. Tumour
Slide 21: Optimized dose delivered can lead to increased efficacy
novecure’ optimized dose delivered can lead to increased efficacy TUMOR TREATING FIELDS DOSE DELIVERED TIME ON xX FIELD INTENSITY xX CONDUCTIVITY om THERAPY TO TUMOR OF TISSUE —_ patientfo rward™ © 2024 Novocure GmbH 21 Ballo MT, et al. Correlation of Tumor Treating Fields Dosimetry to Survival Outc
Slide 22: New lighter, thinner arrays deliver greater intensity
novecure’ new lighter, thinner arrays deliver greater intensity an EXISTING ARRAYS NEW ARRAYS AP channel, 1,364 mAmps AP channel, 1,685 mAmps OV/cm PMA SUPPLEMENT SUBMITTED IN @4 2023 patientforward™ © 2024Novocure GmbH 22 ingthe as pa in Atray performance data obtained from pati
Slide 23: Ongoing trial designs
novecure’ ongoing trial designs - patientfo rward” © 2024 Novocure GmbH 23
Slide 24: PANOVA-3: phase 3 trial in locally advanced pancreatic cancer
novecure’ PANOVA-3: phase 3 trial in locally advanced pancreatic cancer OPEN-LABEL, RANDOMIZED TRIAL DESIGN* TTFields + nab-paclitaxel + gemcitabine screening a nab-paclitaxel + gemcitabine STUDY DESIGN 556 patients with 18-month minimum follow-up Primary endpoint: overall survival Enrollment comple
Slide 25: PANOVA-4: phase 2 trial in metastatic pancreatic cancer
novecure’ PANOVA-4: phase 2 trial in metastatic pancreatic cancer PILOT, SINGLE-ARM TRIAL DESIGN! TTFields + screening and baseline J —atezolizumab + __ CT q8w until sz post-PD _ survival evaluation nab-paclitaxel + progression follow up visit follow-up q3m gemcitabine STUDY DESIGN + 76 patients wit
Slide 26: TRIDENT: phase 3 trial in newly diagnosed glioblastoma
novecure’ TRIDENT: phase 3 trial in newly diagnosed glioblastoma OPEN-LABEL, RANDOMIZED TRIAL DESIGN* TTFields + radiation TTFields + MRI q8w until survival therapy + TMZ maintenance TMZ progression follow-up screening and baseline evaluation Radiation therapy TTFields + MRI q8w until survival + TMZ
Slide 27: LUNAR-2: phase 3 trial in metastatic non-small cell lung cancer
novecure’ LUNAR-2: phase 3 trial in metastatic non-small cell lung cancer OPEN-LABEL RANDOMIZED TRIAL DESIGN TTFields + pembrolizumab + CT/follow-up q3w fi survival platinum-based chemotherapy until progression follow-up screening and baseline evaluation pembrolizumab + platinum-based CT/follow-up q
Slide 28: KEYNOTE B36: phase 2 trial in non-small cell lung cancer
novecure’ KEYNOTE B36: phase 2 trial in locally advanced or metastatic non-small cell lung cancer OPEN-LABEL RANDOMIZED TRIAL DESIGN* TTFields + pembrolizumab - alone follo q3w, _| survival — — screening and baseline evaluation a a 9 6 aa € io) 3 < fy STUDY DESIGN + 100 patients with 12-month minimu
Slide 29: Optune Lua and Optune Gio indications for use and important safety information
novecure’ Optune Lua® and Optune Gio® indications for use and important safety information INDICATIONS * Optune Gio is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). © Optune Gio with temozolomide is indicated for th
Slide 30: Optune Lua and Optune Gio warnings and precautions
novecure’ Optune Lua® and Optune Gio® indications for use and important safety information WARNINGS AND PRECAUTIONS * Optune Gio and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. » The most common (210%) adver